Why $ANCN Anchiano Therapeutics Is Surging Today?
Why AANCN Anchiano Therapeutics Is Surging Today?
Thanks to some news in December in the biopharma space, AANCN stock is racing higher. So what was that news? And what else do you need to know?
AANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december.
The proposed merger will create a public company focused on advancing Chemomab’s lead product, CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need
Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel.
Concurrent with the merger, Chemomab seeks to complete a PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications, as well as to further develop Chemomab’s earlier-stage pipeline.
We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger."
finance.yahoo.com/news/anchiano-therapeutics-chemomab-announce-entry-140000055.html
Thanks to some news in December in the biopharma space, AANCN stock is racing higher. So what was that news? And what else do you need to know?
AANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december.
The proposed merger will create a public company focused on advancing Chemomab’s lead product, CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need
Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel.
Concurrent with the merger, Chemomab seeks to complete a PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications, as well as to further develop Chemomab’s earlier-stage pipeline.
We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger."
finance.yahoo.com/news/anchiano-therapeutics-chemomab-announce-entry-140000055.html
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.